FATE
FATE
NASDAQ · Biotechnology

Fate Therapeutics Inc

$2.39
-0.04 (-1.65%)
As of May 16, 2:11 AM ET ·
Analyst Consensus
Buy
18
Analysts
High
Coverage
Buy 11 61%
Hold 7 39%
Sell 0 0%
Price Target
Analyst Price Target +140.6% upside
Low Target $4.43
Average Target $5.75
High Target $6.69
Current Price $2.39
Current
$2.39
Target
$5.75
$4.43 $5.75 avg $6.69
Scenario Analysis
Bear Case
$4.43
85.4%
Low target
Base Case
$5.75
+140.6%
Avg target
Bull Case
$6.69
+179.9%
High target
Risk/Reward
2.1x
Favorable
Price in Context
52-Week High
$2.47
-3.0% from high
52-Week Low
$0.91
+162.6% from low
Target vs 52W High
$5.75
+133.3% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 40 75% $257.58 +22.4%
AMGN
Amgen Inc
Hold 44 48% $190.87 -41.5%
GILD
Gilead Sciences Inc
Strong Buy 39 79% $362.68 +179.9%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 +0.3%
REGN
Regeneron Pharmaceuticals
Strong Buy 38 79% $76.80 -89.0%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -64.3%
RVMD
Revolution Medicines Inc
Strong Buy 27 96% $114.11 -21.7%
BIIB
Biogen Inc
Buy 43 56% $91.45 -52.6%